Children who lived in apartments or newer buildings were also found to have an increased risk of atopic dermatitis later in life.
Several home environment exposures during childhood were associated with an increased risk of asthma, allergic rhinitis, and atopic dermatitis (AD) later in life, according to study findings published in Science of the Total Environment.
With a majority of time spent indoors, especially at home, researchers noted that certain exposures have been cited to increase risk of asthma and allergic diseases. In the in-home environment, these documented risk factors include dampness and mold, environmental tobacco smoke, chemical emissions, particularly from new materials, and recent painting.
“Asthma and allergic rhinitis often coexist and are the most common comorbidities for AD,” said the study authors. “Few studies have investigated indoor dampness exposure over several decades.”
They collected data on dampness and mold exposure at home from the Respiratory Health in Northern Europe (RHINE) study, a cohort study on development of asthma and allergic diseases that followed adults in Northern Europe over 2 decades (one baseline investigation and 2 follow up investigations every 10 years).
Associations between parental report on the home environment in the RHINE cohort and development of asthma, allergic rhinitis, and AD in the offspring of the RHINE participants were investigated.
A total of 17,881 offspring from Iceland, Norway, Sweden, Denmark, and Estonia were included in the analysis, with home environment exposures of dampness and mold, type of dwelling, construction year, and indoor painting assessed via questionnaire by parents in the first follow up (RHINE II).
“The parents reported 10 years later within the frame of RHINE III offspring's birth year and offspring's asthma, allergic rhinitis, or AD. They also reported dampness and mold at home from RHINE II to RHINE III,” explained researchers.
Overall, prevalence of offspring's asthma before 10 years, asthma after 10 years, allergic rhinitis at any age, and AD at any age were 9.7%, 4.3%, 15.6%, and 17.3 %, respectively. A myriad of exposures were associated with offspring’s asthma or allergic diseases:
Dose-response effects were also observed with longer exposure to dampness and mold regarding offspring's risk of asthma after 10 years and AD (20 years exposure vs 10 years exposure). Older offspring showed increased risk of developing asthma after 10 years and AD.
The study authors concluded that reducing moisture and mold damage at home may be beneficial for occupants with asthma and allergies. “More perspective studies are needed to investigate the effects of building characteristics and other indoor environment exposures on development of atopic diseases,” they added.
Reference
Wang J, Janson C, Malinovschi A, et al. Asthma, allergic rhinitis and atopic dermatitis in association with home environment - The RHINE study. Sci Total Environ. 2022 Sep 8;853:158609. doi:10.1016/j.scitotenv.2022.158609
Prenatal PFAS Exposure Alters Infant Vaccine-Related Immune Cells
August 1st 2025Prenatal exposure to per- and polyfluoroalkyl substances (PFAS), a class of persistent environmental pollutants, was linked to significant shifts in infant T helper cell development, raising concerns about long-term effects on vaccine response, immune regulation, and disease susceptibility.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Advancing Women's Health: CVS Health Leader on Access, Technology, and Breaking Stigmas
December 5th 2024On this episode of Managed Care Cast, we speak with CVS Health's vice president and chief medical officer for women's health and genomics about advancements and challenges in women's health, focusing on care access, technology, and maternal outcomes.
Listen
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More